FRANKFURT (Reuters) - A targeted oral drug combination by Novartis won U.S. approval for use in a wide range of advanced solid tumours that are driven.
FoundationOne CDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumours for whom treatment with Rozlytrek may
FoundationOne CDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid.